LG-120907 (original) (raw)
LG-120907 is a nonsteroidal antiandrogen (NSAA) of the quinoline group which was developed by Ligand Pharmaceuticals along with selective androgen receptor modulators (SARMs) like LG-121071 and was never marketed. The drug is a high-affinity antagonist of the androgen receptor (AR) with a Ki value of 26 nM and has been found to inhibit growth of the ventral prostate and seminal vesicles in male rats without increasing circulating levels of luteinizing hormone or testosterone. However, this tissue selectivity has not been assessed in humans. LG-120907 is orally active and shows greater oral potency than the arylpropionamide NSAA flutamide.
| Property | Value |
|---|---|
| dbo:abstract | LG-120907 is a nonsteroidal antiandrogen (NSAA) of the quinoline group which was developed by Ligand Pharmaceuticals along with selective androgen receptor modulators (SARMs) like LG-121071 and was never marketed. The drug is a high-affinity antagonist of the androgen receptor (AR) with a Ki value of 26 nM and has been found to inhibit growth of the ventral prostate and seminal vesicles in male rats without increasing circulating levels of luteinizing hormone or testosterone. However, this tissue selectivity has not been assessed in humans. LG-120907 is orally active and shows greater oral potency than the arylpropionamide NSAA flutamide. The 7-fluoro derivative of LG-120907, , is also a potent NSAA, and appears to possess greater potency in comparison. Conversely, the 6-ethyl, 8-didesmethyl analogue of LG-120907, LG-121071, is a SARM with potent androgenic activity equivalent to that of dihydrotestosterone (DHT). (en) |
| dbo:casNumber | 179897-43-9 |
| dbo:chEMBL | 350877 |
| dbo:class | dbr:Nonsteroidal_antiandrogen |
| dbo:pubchem | 10851308 |
| dbo:thumbnail | wiki-commons:Special:FilePath/LG-120907.svg?width=300 |
| dbo:wikiPageID | 54522589 (xsd:integer) |
| dbo:wikiPageLength | 4802 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID | 1120576484 (xsd:integer) |
| dbo:wikiPageWikiLink | dbr:Potency_(pharmacology) dbr:Quinoline dbr:Androgen dbr:Androgen_receptor dbr:LG-121071 dbc:Trifluoromethyl_compounds dbr:Oral_administration dbr:Tissue_selectivity dbr:Ligand_Pharmaceuticals dbr:Structural_analogue dbr:Receptor_antagonist dbc:Nonsteroidal_antiandrogens dbr:Fluorine dbr:Flutamide dbr:Cell_growth dbc:Quinolines dbr:Testosterone dbr:Affinity_(pharmacology) dbr:Dihydrotestosterone dbr:Aryl dbr:Selective_androgen_receptor_modulator dbr:Seminal_vesicle dbr:Ethyl_group dbr:Luteinizing_hormone dbr:Nonsteroidal_antiandrogen dbr:Desmethyl dbr:Propionamide dbr:Chemical_derivative dbr:Ventral_prostate dbr:LG-105 |
| dbp:c | 15 (xsd:integer) |
| dbp:casNumber | 179897 (xsd:integer) |
| dbp:chembl | 350877 (xsd:integer) |
| dbp:chemspiderid | 9026602 (xsd:integer) |
| dbp:class | dbr:Nonsteroidal_antiandrogen |
| dbp:f | 3 (xsd:integer) |
| dbp:h | 13 (xsd:integer) |
| dbp:iupacName | 22 (xsd:integer) |
| dbp:n | 2 (xsd:integer) |
| dbp:o | 1 (xsd:integer) |
| dbp:pubchem | 10851308 (xsd:integer) |
| dbp:smiles | CC1C (en) |
| dbp:stdinchi | 1 (xsd:integer) |
| dbp:stdinchikey | MMLSXRYBGYGQEP-UHFFFAOYSA-N (en) |
| dbp:synonyms | (1,2,3,4-Tetrahydro-2,2-dimethyl-6-trifluoromethyl-8-pyridono[5,6-g]quinoline) (en) |
| dbp:wikiPageUsesTemplate | dbt:Androgen_receptor_modulators dbt:Drugbox dbt:Genito-urinary-drug-stub dbt:Reflist |
| dcterms:subject | dbc:Trifluoromethyl_compounds dbc:Nonsteroidal_antiandrogens dbc:Quinolines |
| rdf:type | owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:Drug |
| rdfs:comment | LG-120907 is a nonsteroidal antiandrogen (NSAA) of the quinoline group which was developed by Ligand Pharmaceuticals along with selective androgen receptor modulators (SARMs) like LG-121071 and was never marketed. The drug is a high-affinity antagonist of the androgen receptor (AR) with a Ki value of 26 nM and has been found to inhibit growth of the ventral prostate and seminal vesicles in male rats without increasing circulating levels of luteinizing hormone or testosterone. However, this tissue selectivity has not been assessed in humans. LG-120907 is orally active and shows greater oral potency than the arylpropionamide NSAA flutamide. (en) |
| rdfs:label | LG-120907 (en) |
| owl:sameAs | wikidata:LG-120907 https://global.dbpedia.org/id/3c1Pa |
| prov:wasDerivedFrom | wikipedia-en:LG-120907?oldid=1120576484&ns=0 |
| foaf:depiction | wiki-commons:Special:FilePath/LG-120907.svg |
| foaf:isPrimaryTopicOf | wikipedia-en:LG-120907 |
| is dbo:wikiPageRedirects of | dbr:LG-120,907 dbr:LG120,907 dbr:LG120907 dbr:LGD-120,907 dbr:LGD-120907 dbr:LGD120,907 dbr:LGD120907 dbr:LGD_120,907 dbr:LGD_120907 dbr:LG_120,907 dbr:LG_120907 |
| is dbo:wikiPageWikiLink of | dbr:LG121071 dbr:LG-120,907 dbr:LG120,907 dbr:LG120907 dbr:LGD-120,907 dbr:LGD-120907 dbr:LGD120,907 dbr:LGD120907 dbr:LGD_120,907 dbr:LGD_120907 dbr:LG_120,907 dbr:LG_120907 |
| is foaf:primaryTopic of | wikipedia-en:LG-120907 |
